Clinical Trial Update: A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure [Phase 2]

View source ↗

Summary

Phase 2 study comparing once-daily versus twice-daily dosing of valsartan in patients with stable chronic heart failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• VALSARTAN (Valsartan)

Snippet

Sponsor: Novartis | Conditions: Chronic Heart Failure | Phase 2 | Status: COMPLETED